共 50 条
EVALUATION OF NEW ANTIINFECTIVE DRUGS FOR THE TREATMENT OF SYPHILIS
被引:7
|作者:
RONALD, AR
SILVERMAN, M
MCCUTCHAN, JA
COREY, L
HANDSFIELD, HH
机构:
[1] UNIV MANITOBA,DEPT INTERNAL MED,WINNIPEG R3T 2N2,MANITOBA,CANADA
[2] UNIV MANITOBA,DEPT MED MICROBIOL,WINNIPEG R3T 2N2,MANITOBA,CANADA
[3] ST BONIFACE GEN HOSP,WINNIPEG R2H 2A6,MANITOBA,CANADA
[4] UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093
[5] UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195
[6] UNIV WASHINGTON,SCH MED,DEPT LAB MED,SEATTLE,WA 98195
[7] SEATTLE KING CTY DEPT PUBL HLTH,SEATTLE,WA 98104
关键词:
D O I:
10.1093/clind/15.Supplement_1.S140
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Syphilis is caused by Treponema pallidum, a spirochetal bacterium pathogenic only for humans. The clinical course of disease is divided into three stages interspersed by periods of latency. Penicillin remains the treatment of choice for all stages of infection; tetracycline or erythromycin may be used as therapeutic alternatives in defined circumstances. Patients enrolled in clinical trials should be evaluated clinically, microscopically, and serologically for the presence of the spirochete. All participants, after undergoing counseling and giving informed consent, should be tested for infection with human immunodeficiency virus. Specific criteria exist for diagnosis of syphilis and response to therapy. It may be desirable to perform a small, uncontrolled, open trial of a new anti-infective drug for the collection of preliminary evidence of efficacy. A larger-scale, randomized, active-control comparative clinical trial is necessary to prove efficacy.
引用
收藏
页码:S140 / S147
页数:8
相关论文